A Takeda spokesperson told Fierce Biotech that it was on track to open its new R&D facility being developed by BioMed Realty ...
Ever since 6-year-old Emily Whitehead became the first patient to receive CAR-T cell therapy in 2012, when T cells were ...
Following Moderna's public rebuke of the FDA's refusal to take up its application for a next-gen flu vaccine, the regulator has doubled down and accused Moderna of potentially putting patients at risk ...
During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and the Department of Health ...
Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra. | Madrigal Pharmaceuticals is continuing to ...
GE HealthCare has launched a new technology designed to help hospitals keep up with the maintenance and repair demands of a growing number of connected medical devices. | GE HealthCare has launched a ...
A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma exacerbation ...
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...
In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner ...
Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...
CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. | The deal allows CSL to ...
Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results